Takeda Tries Again To Shake Actos Antitrust Claims

Law360, New York (October 23, 2018, 9:22 PM EDT) -- Takeda Pharmaceutical Co. told a New York federal judge Tuesday that it’s common practice for drugmakers to draw loose connections between their products and their intellectual property in a national register of government-approved drugs, arguing that an antitrust lawsuit allegedly painting that list as scripture should be dismissed for a second time.

It’s not Takeda’s fault, company counsel told U.S. District Judge Ronnie Abrams, if information provided for the U.S. Food and Drug Administration’s Orange Book delayed or scared off generic competition to its brand-name Type 2 diabetes treatment, Actos.

“People understand that, in general, you list patents that are related...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!